RUSCKOWSKI STEPHEN H
RUSCKOWSKI STEPHEN H's purchase track record
RUSCKOWSKI STEPHEN H has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/29/2026 | ORCL | $3.48M | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Tenet Healthcare Raises 2026 Outlook, Analysts Lift Targets. Tenet Healthcare recently raised its 2026 financial outlook, prompting analysts like Guggenheim to increase price targets to $307. This positive guidance has driven the stock higher, with the average analyst target now sitting at $285.32. While the company is trading near its 52-week high, questions remain about whether this recent strength is fully reflected in the current valuation.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Baxter International publishes inaugural Connected Hospital Report. Baxter International released its first Connected Hospital Report, highlighting its role in remote cardiac monitoring and digital health infrastructure. The company is also featured in recent discussions regarding potential warning signs in Wall Street favorites and overlooked investment angles. These developments provide context for the stock's current position within its 52-week range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus. Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.
Transaction History
| ORCL | ▲ Buy | Open Market | 25,000 | $3.5M | 9/29/2026 | View on chart |
| THC | ▲ Buy | Option Exercise | 1,551 | — | 5/23/2025 | View on chart |
| BAX | ▲ Buy | Grant | 7,183 | $0 | 5/6/2025 | View on chart |
| BAX | ▲ Buy | Grant | 5,952 | $0 | 5/7/2024 | View on chart |
| BAX | ▲ Buy | Grant | 3,049 | $0 | 8/21/2023 | View on chart |
| THC | ▲ Buy | Grant | 2,846 | $0 | 5/26/2023 | View on chart |
| DGX | ▲ Buy | Grant | 82,631 | $12.2M | 3/6/2023 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 38,604 | $5.7M | 3/6/2023 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 3,496 | $492K | 3/1/2023 | View on chart |
| DGX | ▲ Buy | Grant | 20,059 | $0 | 2/23/2023 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 5,826 | $861K | 2/23/2023 | View on chart |
| DGX | ▲ Buy | Option Exercise | 10,037 | $1.0M | 5/25/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 6,821 | $959K | 5/25/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 2,565 | $363K | 5/25/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 651 | $93K | 5/25/2022 | View on chart |
| DGX | ▲ Buy | Option Exercise | 14,854 | $1.3M | 5/25/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 4,131 | $584K | 5/25/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 900 | $128K | 5/25/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 9,823 | $1.4M | 5/25/2022 | View on chart |
| DGX | ▲ Buy | Option Exercise | 126,126 | $13.1M | 5/24/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 126,126 | $17.7M | 5/24/2022 | View on chart |
| DGX | ▲ Buy | Option Exercise | 156,282 | $13.5M | 5/24/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 156,282 | $21.9M | 5/24/2022 | View on chart |
| DGX | ▲ Buy | Option Exercise | 34,898 | $3.6M | 5/23/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 33,898 | $4.7M | 5/23/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 800 | $113K | 5/23/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 200 | $28K | 5/23/2022 | View on chart |
| DGX | ▲ Buy | Option Exercise | 42,568 | $3.7M | 5/23/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 41,268 | $5.8M | 5/23/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 1,000 | $142K | 5/23/2022 | View on chart |
| DGX | ▼ Sell | Open Market | 300 | $43K | 5/23/2022 | View on chart |
| DGX | ▲ Buy | Grant | 70,184 | $9.1M | 3/7/2022 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 32,570 | $4.2M | 3/7/2022 | View on chart |
| DGX | ▲ Buy | Grant | 22,510 | $0 | 2/24/2022 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 7,463 | $971K | 2/23/2022 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 2,255 | $294K | 2/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Oracle: No Recent Company News
Oracle has not had any new company‑specific announcements in the past week. The recent news items listed relate to other technology firms and do not directly affect Oracle’s operations or outlook. Investors can continue to rely on existing fundamentals and market data for guidance.
Oracle: No Recent Company News. Oracle has not had any new company‑specific announcements in the past week. The recent news items listed relate to other technology firms and do not directly affect Oracle’s operations or outlook. Investors can continue to rely on existing fundamentals and market data for guidance.